BACKGROUND: Bax, Bcl-2, and p53 proteins are involved in the regulation of apoptosis and have been reported to correlate with prognosis in several tumor types. METHODS: Bax, Bcl-2, p53, and the level of spontaneous apoptosis were evaluated in formalin fixed, paraffin embedded pretreatment specimens from 85 T1-4 squamous cell carcinomas (SCCs) of the tongue by immunohistochemical methods. The percentage of apoptotic cells labeled by the terminal deoxynucleotidyl transferase (TdT)-mediated dUTP labeling (TUNEL) method was expressed as an apoptotic index (AI). For Bax and Bcl-2 evaluation, the fraction of tumor cells stained and the staining intensities were given scores that were added together, resulting in a final score. p53 immunostaining was expressed as a percentage of positive cells. RESULTS: High AI was significantly associated with high Bax expression (P = 0.0122) and highly differentiated tumors (P = 0.0062). No correlation was found between AI and Bcl-2 expression. There was no correlation between p53 positivity and any of the other apoptosis-related parameters. Whereas low AI scores and low Bax expression correlated significantly with poor prognosis (P = 0.0053 and P = 0.0012, respectively), a low Bcl-2 expression was associated with a favorable clinical outcome (P = 0.0262). Patients with a high Bcl-2/Bax expression ratio had a significantly poorer prognosis than those with a low ratio (P < 0.0001). Multivariate analysis revealed that Bax expression, the Bcl-2/Bax expression ratio, and the T and N classifications were significantly independent prognostic variables. The Bcl-2/Bax expression ratio was the strongest independent prognostic parameter. CONCLUSIONS: AI, individual Bax and Bcl-2 expression, and particularly the Bcl-2/Bax expression ratio have prognostic value in SCC of the tongue. Copyright 1999 American Cancer Society.
BACKGROUND:Bax, Bcl-2, and p53 proteins are involved in the regulation of apoptosis and have been reported to correlate with prognosis in several tumor types. METHODS:Bax, Bcl-2, p53, and the level of spontaneous apoptosis were evaluated in formalin fixed, paraffin embedded pretreatment specimens from 85 T1-4 squamous cell carcinomas (SCCs) of the tongue by immunohistochemical methods. The percentage of apoptotic cells labeled by the terminal deoxynucleotidyl transferase (TdT)-mediated dUTP labeling (TUNEL) method was expressed as an apoptotic index (AI). For Bax and Bcl-2 evaluation, the fraction of tumor cells stained and the staining intensities were given scores that were added together, resulting in a final score. p53 immunostaining was expressed as a percentage of positive cells. RESULTS: High AI was significantly associated with high Bax expression (P = 0.0122) and highly differentiated tumors (P = 0.0062). No correlation was found between AI and Bcl-2 expression. There was no correlation between p53 positivity and any of the other apoptosis-related parameters. Whereas low AI scores and low Bax expression correlated significantly with poor prognosis (P = 0.0053 and P = 0.0012, respectively), a low Bcl-2 expression was associated with a favorable clinical outcome (P = 0.0262). Patients with a high Bcl-2/Bax expression ratio had a significantly poorer prognosis than those with a low ratio (P < 0.0001). Multivariate analysis revealed that Bax expression, the Bcl-2/Bax expression ratio, and the T and N classifications were significantly independent prognostic variables. The Bcl-2/Bax expression ratio was the strongest independent prognostic parameter. CONCLUSIONS: AI, individual Bax and Bcl-2 expression, and particularly the Bcl-2/Bax expression ratio have prognostic value in SCC of the tongue. Copyright 1999 American Cancer Society.
Authors: M Re; A Zizzi; L Ferrante; D Stramazzotti; G Goteri; F M Gioacchini; F Olivieri; G Magliulo; C Rubini Journal: Eur Arch Otorhinolaryngol Date: 2014-01-09 Impact factor: 2.503
Authors: Atsushi Imai; Benjamin D Zeitlin; Fernanda Visioli; Zhihong Dong; Zhaocheng Zhang; Sudha Krishnamurthy; Emily Light; Frank Worden; Shaomeng Wang; Jacques E Nör Journal: Cancer Res Date: 2011-12-08 Impact factor: 12.701
Authors: Li Yan Khor; Jennifer Moughan; Tahseen Al-Saleem; Elizabeth H Hammond; Varagur Venkatesan; Seth A Rosenthal; Mark A Ritter; Howard M Sandler; Gerald E Hanks; William U Shipley; Alan Pollack Journal: Clin Cancer Res Date: 2007-06-15 Impact factor: 12.531
Authors: Paul L Swiecicki; Emily Bellile; Assuntina G Sacco; Alexander T Pearson; Jeremy M G Taylor; Trachette L Jackson; Douglas B Chepeha; Matthew E Spector; Andrew Shuman; Kelly Malloy; Jeffrey Moyer; Erin McKean; Scott McLean; Ammar Sukari; Gregory T Wolf; Avraham Eisbruch; Mark Prince; Carol Bradford; Thomas E Carey; Shaomeng Wang; Jacques E Nör; Francis P Worden Journal: Invest New Drugs Date: 2016-05-26 Impact factor: 3.850